BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 12718877)

  • 1. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
    Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
    Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARF differentially modulates apoptosis induced by E2F1 and Myc.
    Russell JL; Powers JT; Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
    Mol Cell Biol; 2002 Mar; 22(5):1360-8. PubMed ID: 11839803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIF loss impairs Myc-induced lymphomagenesis.
    Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
    Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
    Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
    Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
    Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
    Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
    Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
    J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
    Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
    Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.
    Maclean KH; Dorsey FC; Cleveland JL; Kastan MB
    J Clin Invest; 2008 Jan; 118(1):79-88. PubMed ID: 18097482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphomagenesis and female-specific lethality in p53-deficient mice occur independently of E2f1.
    Wloga EH; Criniti V; Yamasaki L; Bronson RT
    Nat Cell Biol; 2004 Jul; 6(7):565-7; author reply 567-8. PubMed ID: 15232580
    [No Abstract]   [Full Text] [Related]  

  • 14. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
    Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
    Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBV latent membrane protein 2A orchestrates p27
    Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
    Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
    Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
    Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
    Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
    Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc lacks E2F1's ability to suppress skin carcinogenesis.
    Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
    Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.